ANGELALIGN Reports 2025 Adjusted Net Profit of $43.77 Million, Up 62.99%

Stock News03-27

ANGELALIGN (06699) announced its 2025 financial results. Revenue increased by 37.8% year-on-year to $370 million. Net profit rose by 163.0% to $26.3 million, while the adjusted net profit reached $43.77 million, representing a growth of 62.99% compared to the previous year. Earnings per share were $0.17. The Board has proposed a final dividend of HK$0.48 per share and a special dividend of HK$4.99 per share, bringing the total distribution to HK$5.47 per share. The improvement in profitability was attributed to increased revenue and the operational leverage gained from the Group's global infrastructure, alongside the timing of certain operational and legal expenses. The year 2025 marked a period of sustained global growth and continuous optimization of operational leverage for the Group. The company achieved robust business growth in markets outside the Chinese mainland by winning clients with its outstanding clinical performance. Simultaneously, its leading market position was further strengthened across all customer segments within the Chinese mainland market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183435824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183435824","market":"sg","top_or_hot":-1,"title":"ANGELALIGN Reports 2025 Adjusted Net Profit of $43.77 Million, Up 62.99%","media":"Stock News","content":"<p>ANGELALIGN (06699) announced its 2025 financial results. Revenue increased by 37.8% year-on-year to $370 million. Net profit rose by 163.0% to $26.3 million, while the adjusted net profit reached $43.77 million, representing a growth of 62.99% compared to the previous year. Earnings per share were $0.17. The Board has proposed a final dividend of HK$0.48 per share and a special dividend of HK$4.99 per share, bringing the total distribution to HK$5.47 per share. The improvement in profitability was attributed to increased revenue and the operational leverage gained from the Group's global infrastructure, alongside the timing of certain operational and legal expenses. The year 2025 marked a period of sustained global growth and continuous optimization of operational leverage for the Group. The company achieved robust business growth in markets outside the Chinese mainland by winning clients with its outstanding clinical performance. Simultaneously, its leading market position was further strengthened across all customer segments within the Chinese mainland market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANGELALIGN Reports 2025 Adjusted Net Profit of $43.77 Million, Up 62.99%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANGELALIGN Reports 2025 Adjusted Net Profit of $43.77 Million, Up 62.99%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-27 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ANGELALIGN (06699) announced its 2025 financial results. Revenue increased by 37.8% year-on-year to $370 million. Net profit rose by 163.0% to $26.3 million, while the adjusted net profit reached $43.77 million, representing a growth of 62.99% compared to the previous year. Earnings per share were $0.17. The Board has proposed a final dividend of HK$0.48 per share and a special dividend of HK$4.99 per share, bringing the total distribution to HK$5.47 per share. The improvement in profitability was attributed to increased revenue and the operational leverage gained from the Group's global infrastructure, alongside the timing of certain operational and legal expenses. The year 2025 marked a period of sustained global growth and continuous optimization of operational leverage for the Group. The company achieved robust business growth in markets outside the Chinese mainland by winning clients with its outstanding clinical performance. Simultaneously, its leading market position was further strengthened across all customer segments within the Chinese mainland market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1183435824","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183435824","pubTimestamp":1774622303,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ANGELALIGN (06699) announced its 2025 financial results. Revenue increased by 37.8% year-on-year to $370 million. Net profit rose by 163.0% to $26.3 million, while the adjusted net profit reached...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1100":"医疗保健设备","06699":"时代天使","BK1593":"医美概念股","BK1587":"次新股"},"translate_title":"ANGELALIGN报告2025年调整后净利润为4377万美元，增长62.99%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06699":1},"content_text":"ANGELALIGN (06699) announced its 2025 financial results. Revenue increased by 37.8% year-on-year to $370 million. Net profit rose by 163.0% to $26.3 million, while the adjusted net profit reached $43.77 million, representing a growth of 62.99% compared to the previous year. Earnings per share were $0.17. The Board has proposed a final dividend of HK$0.48 per share and a special dividend of HK$4.99 per share, bringing the total distribution to HK$5.47 per share. The improvement in profitability was attributed to increased revenue and the operational leverage gained from the Group's global infrastructure, alongside the timing of certain operational and legal expenses. The year 2025 marked a period of sustained global growth and continuous optimization of operational leverage for the Group. The company achieved robust business growth in markets outside the Chinese mainland by winning clients with its outstanding clinical performance. Simultaneously, its leading market position was further strengthened across all customer segments within the Chinese mainland market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183435824","isCrawlerRequest":true}